GlassScriptPhysician profile
Bijal A Dave
NPI 1770733321
$25,077.96
in general payments reported to CMS, 2019-2025
45 companies · $1,913 in 2025
The $1,913 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $943 · 2020: $1,285 · 2021: $2,186 · 2022: $15K · 2023: $1,662 · 2024: $2,141 · 2025: $1,913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,715.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $15,973.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,431.22 | 2019-2025 | Jardiance, Tradjenta |
| Boston Scientific Corporation | $978.88 | 2020-2025 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $803.57 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $797.30 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $713.46 | 2021-2025 | Vraylar, Ubrelvy, Synthroid |
| Novartis Pharmaceuticals Corporation | $485.37 | 2019-2024 | |
| Lilly USA, LLC | $466.99 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $403.20 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $330.04 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $253.74 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $227.75 | 2019-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $199.51 | 2019-2022 | |
| Corcept Therapeutics | $197.34 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $196.95 | 2019-2025 | Shingrix, Arexvy |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bijal Dave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.